{"success":true,"data":{"pressRelease":{"id":"75297","rtpr_id":"nGNX8jLJRN","ticker":"IMDX","exchange":"NASDAQ","all_tickers":["IMDX"],"title":"IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper","author":"Globe Newswire","published_at":"2026-06-29T12:00:01.384Z","article_body":"* Key member of management ranks at top 2% of researchers in the field of\nlaboratory diagnostics and top 2.5% of all researchers worldwide, based on\nH-index of 58\n* Recent studies advanced science of molecular diagnostic testing for\ntransplanted organ rejection, published in Clinical Chemistry, Transplant\nInternational, American Journal of Transplantation and Nephrology Dialysis\nTransplantation, among others\nNASHVILLE, Tenn., June 29, 2026 (GLOBE NEWSWIRE) -- Insight Molecular\nDiagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that its Chief\nScience Officer, Prof. Dr. Ekkehard Schuetz. M.D., Ph.D., has published his\n200th scientific article.\n\nDr. Schuetz and Dr. Julia Beck are credited as co-inventors of the dd-cfDNA\ntesting technology that underpins iMDx’s entire GraftAssure family of\nassays. This technology was acquired by iMDx (formerly known as Oncocyte\nCorporation) in 2021 through the acquisition of Chronix Biomedical, Inc., of\nwhich Dr. Schuetz was CEO. Dr. Schuetz has been deeply rooted in the academic\nand scientific communities for 35 years.\n\nWith an H-index of 58, a metric that measures both the productivity and the\ncitation impact of a researcher's publications, Dr. Schuetz is ranked in the\ntop 2.5% of all listed 2.6 million researchers worldwide (according to the AD\nScientific Index\n(https://www.globenewswire.com/Tracker?data=Pod9fMxHSQ2eXcq_elGiJ57TTxKbhSltnMnxDuPn4jhU2D5JwK2oJ9eWpsRIfGkdtaYOCNtmKnS6j0x608yenil00nEn0drDWao4EMh0O6fzYqjuPkc8v8n6GGhnvxkt))\nand in the top 2% of researchers in the field of laboratory diagnostics, which\nencompasses the fields of medical biochemistry, medical biology, chemical\npathology, and clinical chemistry. His work has been cited more than 11,000\ntimes according to Google Scholar.\n\n“It’s been an absolute pleasure watching Ekke work. His scientific\nintegrity and curiosity shine throughout his publications. I join everyone at\niMDx in congratulating Dr. Schuetz on this monumental achievement,” iMDx CEO\nJosh Riggs said. “Dr. Schuetz is a well-known scientific leader and key\nmember of the management team at iMDx. He also is one of the original\ninventors of the underlying science in our flagship technology that is in\nGraftAssure. His presence as Chief Science Officer is meaningfully validating\nfor the company — the scientist who built our core technology is still\nrunning it, and we benefit from this scientific continuity. The GraftAssure\ntechnology and the data support behind it are all credited to Dr. Schuetz’s\nlife's work.”\n\nDr. Schuetz commented, “For over three decades I have been actively\npublishing in the field of laboratory medicine and molecular diagnostics; and\nduring the past 15 years, generating the clinical evidence base rationalizing\nthe preferred use of dd-cfDNA technology. Studies we conducted at iMDx and\nbefore with my academic partners, for example, helped to establish the\ncorrelation between microvascular and vascular inflammation and elevated\ndd-cfDNA in blood plasma.”\n\nDr. Schuetz co-authored the first randomized interventional study\n(https://www.globenewswire.com/Tracker?data=KPFVP42KCDMp31I8__2pTnXlhMzMPO9vwCf2noh7vUit6FSXekJBWEJS5T5Mqe0x7T7zSOBinlBmMOMMNoNT92PZr6TIwf7eSRYTHI7Dayb4arTJI_uLEyNqJVwtcd01sQF34rSO588UciDzc9MZeUckcnM_lPf7nYlb1nR3kgaTIPdwZ31GVDZHfeTTJAfu)\nto validate any dd-cfDNA technology as a rule-in test for biopsy in a\nhigh-risk population, published in Nephrology Dialysis Transplantation.\n\nDr. Schuetz has also co-led key clinical studies for iMDx at University\nHospital Heidelberg, such as the head-to-head comparison study\n(https://www.globenewswire.com/Tracker?data=aKjLp06TyTowBLs6x7xYBOupW6JkcEjfw0sDOQef_CNL3MpDlI35Z0LS44CSKq992zhLeN0ZZRl7LSrd7zS_aWvTkjIU9W60gkk-DyMhnP1vvpl0ZAUwrIkFompptKrCS4aL6WKs9HRgg-eMH8I4PY-o1UC0hHJ2tLLG1QcFf8kPB70zzOopzSK8Xhmz63VL)\nthat was published in Clinical Chemistry — the first direct comparison of\ntwo commercially available dd-cfDNA test kits based on single nucleotide\npolymorphisms, or SNPs — which confirmed that a digital PCR approach showed\nimproved analytical sensitivity over NGS-based approaches.\n\nHis recent accomplishment also includes co-authoring groundbreaking studies on\nimproving the clinical usability of dd-cfDNA by combining percentage and\nabsolute concentrations (known as CM-Score) of the biomarker, conducted with\ninvestigators from Heidelberg University Hospital and Charité –\nUniversitätsmedizin Berlin:\n* iMDx GraftAssure assay sets new standard in screening kidney transplant\npatients, per American Journal of Transplantation\n(https://investors.imdxinc.com/news-releases/2026/06-11-2026-211734810)\n* Second study affirms superiority of iMDx GraftAssure assay’s proprietary\ndd-cfDNA Combination Model score, per Transplant International\n(https://investors.imdxinc.com/news-releases/2026/03-13-2026-120126981)\nUnder Dr. Schuetz’s leadership, iMDx’s de novo FDA submission for\nmarketing authorization of its GraftAssureDx kit earlier this year represents\na major milestone toward iMDx’s strategic goal to become the leading\nprovider of dd-cfDNA testing technology, and decentralizing access to\nmolecular diagnostic transplant rejection testing.\n\nAbout iMDx’s GraftAssure technology\n\niMDx is at a pivotal stage in commercializing its GraftAssure technology,\nwhich iMDx expects to be an industry-transforming transplanted organ rejection\nmonitoring test. The company aims to deliver proven, more affordable, faster\ntests that can be run in-house at local transplant center laboratories. iMDx\nhas designed a molecular test that it can sell as a test kit to help enable\ntransplant center laboratories to run tests locally and deliver critical test\nresults far more quickly than the current send-out tests. The company is now\nseeking FDA marketing authorization to sell these kits to transplant centers\nin the U.S.\n* Over time, iMDx sees three potential paradigm shifts in transplanted organ\nhealth monitoring:  * Bringing testing closer to the patient: The first is a\nshift in where donor-derived cell-free DNA (dd-cfDNA) testing is performed –\nmigrating out of centralized reference laboratories and into hospital-based\nlaboratories capable of delivering results locally. The company seeks to\ndemonstrate that in-house testing is better for patients and physicians. (As a\nreminder, dd-cfDNA is an established biomarker for assessing the health of a\ntransplanted organ through a simple blood draw.)\n* Expanding the clinical role of dd-cfDNA: The second is the growing potential\nfor dd-cfDNA testing, powered by digital PCR technology, to support earlier\ndetection of allograft injury, longitudinal monitoring of transplant health,\nand assessment of response to emerging anti-rejection therapies.\n* Advancing from rule-out to comprehensive decision support: The third is a\ntransition from the current rule-out-biopsy testing paradigm toward a more\ncomprehensive rule-out and rule-in approach, enabled by GraftAssure’s\nability to measure both dd-cfDNA percentage and absolute, or true,\nconcentrations as copies per milliliter of plasma.\niMDx Transplant Products and Product Candidates in Development\n\niMDx’s flagship transplant testing technology quantifies a molecular\nbiomarker known as donor-derived cell-free DNA (dd-cfDNA). The Company’s\nscientists in Germany and the U.S. have played a critical role over the past\ndecade in developing the science that helped establish dd-cfDNA as a trusted\nbiomarker of transplant rejection. iMDx is commercializing this technology\nusing a market-disruptive business strategy. Under the GraftAssure™ brand,\niMDx’s transplant diagnostics include the following:\n* GraftAssureCore – The company’s laboratory-developed test (LDT),\ncurrently reimbursed by CMS and performed at iMDx’s CLIA-certified\nlaboratory in Franklin, Tennessee.\n* GraftAssureIQ – A research-use-only (RUO) kit intended and labeled for\nnon-clinical applications.\n* GraftAssureDx – The in vitro diagnostic (IVD) kit currently under FDA\nreview for use in clinical decision-making.\nAbout Insight Molecular Diagnostics, Inc.\n\nInsight Molecular Diagnostics is a pioneering diagnostics technology company\nwhose mission is to democratize access to novel molecular diagnostic testing\nto improve patient outcomes. Investors may visit\nhttps://investors.imdxinc.com/ for more information.\n\nGraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, GraftAssure™,\nDetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular\nDiagnostics Inc.\n\nForward-Looking Statements \nAny statements that are not historical fact (including, but not limited to,\nstatements that contain words such as “will,” “believes,” “plans,”\n“anticipates,” “expects,” “estimates,” “may,” and similar\nexpressions) are forward-looking statements. These statements include those\npertaining to, among other things, expected FDA marketing authorization to\nsell GraftAssureDx, anticipated paradigm shifts in transplanted organ health\nmonitoring, transplant and other product candidates in development, and\nother statements about the future expectations, beliefs, goals, plans, or\nprospects expressed by management.   \n\nForward-looking statements involve risks and uncertainties, including, without\nlimitation, risks inherent in the development and/or commercialization of\ndiagnostic tests or products, uncertainty in the results of clinical trials or\nregulatory approvals, the capacity of Insight Molecular Diagnostics’\nthird-party supplied blood sample analytic system to provide consistent and\nprecise analytic results on a commercial scale, potential interruptions to\nsupply chains, the need and ability to obtain future capital, maintenance of\nintellectual property rights in all applicable jurisdictions, obligations to\nthird parties with respect to licensed or acquired technology and products,\nthe need to obtain third party reimbursement for patients’ use of any\ndiagnostic tests Insight Molecular Diagnostics or its subsidiaries\ncommercialize in applicable jurisdictions, and risks inherent in strategic\ntransactions such as the potential failure to realize anticipated benefits,\nlegal, regulatory or political changes in the applicable jurisdictions,\naccounting and quality controls, potential greater than estimated allocations\nof resources to develop and commercialize technologies, or potential failure\nto maintain any laboratory accreditation or certification. Actual results may\ndiffer materially from the results anticipated in these forward-looking\nstatements and accordingly such statements should be evaluated together with\nthe many uncertainties that affect the business of Insight Molecular\nDiagnostics, particularly those mentioned in the “Risk Factors” and other\ncautionary statements found in Insight Molecular Diagnostics’ Securities and\nExchange Commission (SEC) filings, which are available from the SEC’s\nwebsite. You are cautioned not to place undue reliance on forward-looking\nstatements, which speak only as of the date on which they were made. Insight\nMolecular Diagnostics undertakes no obligation to update such statements\nto reflect events that occur or circumstances that exist after the date on\nwhich they were made, except as required by law.   \n\nFDA \nCAUTION: This press release concerns certain products that are under clinical\ninvestigation, and which have not yet been cleared or authorized for marketing\nby the U.S. Food and Drug Administration. These products are currently limited\nby federal law to investigational use, and no representation is made as to the\nsafety or effectiveness of these products for the purposes for which they are\nbeing investigated. \n\nInvestor Contact: \nDouglas Farrell\nLifeSci Advisors LLC \nimdx@lifesciadvisors.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/418fe8d1-a6a4-4025-84ba-56f14ee83865)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8jLJRN","title":"IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper","author":"Globe Newswire","ticker":"IMDX","created":"2026-06-29T12:00:01.384Z","tickers":["IMDX"],"exchange":"NASDAQ","article_body":"* Key member of management ranks at top 2% of researchers in the field of\nlaboratory diagnostics and top 2.5% of all researchers worldwide, based on\nH-index of 58\n* Recent studies advanced science of molecular diagnostic testing for\ntransplanted organ rejection, published in Clinical Chemistry, Transplant\nInternational, American Journal of Transplantation and Nephrology Dialysis\nTransplantation, among others\nNASHVILLE, Tenn., June 29, 2026 (GLOBE NEWSWIRE) -- Insight Molecular\nDiagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that its Chief\nScience Officer, Prof. Dr. Ekkehard Schuetz. M.D., Ph.D., has published his\n200th scientific article.\n\nDr. Schuetz and Dr. Julia Beck are credited as co-inventors of the dd-cfDNA\ntesting technology that underpins iMDx’s entire GraftAssure family of\nassays. This technology was acquired by iMDx (formerly known as Oncocyte\nCorporation) in 2021 through the acquisition of Chronix Biomedical, Inc., of\nwhich Dr. Schuetz was CEO. Dr. Schuetz has been deeply rooted in the academic\nand scientific communities for 35 years.\n\nWith an H-index of 58, a metric that measures both the productivity and the\ncitation impact of a researcher's publications, Dr. Schuetz is ranked in the\ntop 2.5% of all listed 2.6 million researchers worldwide (according to the AD\nScientific Index\n(https://www.globenewswire.com/Tracker?data=Pod9fMxHSQ2eXcq_elGiJ57TTxKbhSltnMnxDuPn4jhU2D5JwK2oJ9eWpsRIfGkdtaYOCNtmKnS6j0x608yenil00nEn0drDWao4EMh0O6fzYqjuPkc8v8n6GGhnvxkt))\nand in the top 2% of researchers in the field of laboratory diagnostics, which\nencompasses the fields of medical biochemistry, medical biology, chemical\npathology, and clinical chemistry. His work has been cited more than 11,000\ntimes according to Google Scholar.\n\n“It’s been an absolute pleasure watching Ekke work. His scientific\nintegrity and curiosity shine throughout his publications. I join everyone at\niMDx in congratulating Dr. Schuetz on this monumental achievement,” iMDx CEO\nJosh Riggs said. “Dr. Schuetz is a well-known scientific leader and key\nmember of the management team at iMDx. He also is one of the original\ninventors of the underlying science in our flagship technology that is in\nGraftAssure. His presence as Chief Science Officer is meaningfully validating\nfor the company — the scientist who built our core technology is still\nrunning it, and we benefit from this scientific continuity. The GraftAssure\ntechnology and the data support behind it are all credited to Dr. Schuetz’s\nlife's work.”\n\nDr. Schuetz commented, “For over three decades I have been actively\npublishing in the field of laboratory medicine and molecular diagnostics; and\nduring the past 15 years, generating the clinical evidence base rationalizing\nthe preferred use of dd-cfDNA technology. Studies we conducted at iMDx and\nbefore with my academic partners, for example, helped to establish the\ncorrelation between microvascular and vascular inflammation and elevated\ndd-cfDNA in blood plasma.”\n\nDr. Schuetz co-authored the first randomized interventional study\n(https://www.globenewswire.com/Tracker?data=KPFVP42KCDMp31I8__2pTnXlhMzMPO9vwCf2noh7vUit6FSXekJBWEJS5T5Mqe0x7T7zSOBinlBmMOMMNoNT92PZr6TIwf7eSRYTHI7Dayb4arTJI_uLEyNqJVwtcd01sQF34rSO588UciDzc9MZeUckcnM_lPf7nYlb1nR3kgaTIPdwZ31GVDZHfeTTJAfu)\nto validate any dd-cfDNA technology as a rule-in test for biopsy in a\nhigh-risk population, published in Nephrology Dialysis Transplantation.\n\nDr. Schuetz has also co-led key clinical studies for iMDx at University\nHospital Heidelberg, such as the head-to-head comparison study\n(https://www.globenewswire.com/Tracker?data=aKjLp06TyTowBLs6x7xYBOupW6JkcEjfw0sDOQef_CNL3MpDlI35Z0LS44CSKq992zhLeN0ZZRl7LSrd7zS_aWvTkjIU9W60gkk-DyMhnP1vvpl0ZAUwrIkFompptKrCS4aL6WKs9HRgg-eMH8I4PY-o1UC0hHJ2tLLG1QcFf8kPB70zzOopzSK8Xhmz63VL)\nthat was published in Clinical Chemistry — the first direct comparison of\ntwo commercially available dd-cfDNA test kits based on single nucleotide\npolymorphisms, or SNPs — which confirmed that a digital PCR approach showed\nimproved analytical sensitivity over NGS-based approaches.\n\nHis recent accomplishment also includes co-authoring groundbreaking studies on\nimproving the clinical usability of dd-cfDNA by combining percentage and\nabsolute concentrations (known as CM-Score) of the biomarker, conducted with\ninvestigators from Heidelberg University Hospital and Charité –\nUniversitätsmedizin Berlin:\n* iMDx GraftAssure assay sets new standard in screening kidney transplant\npatients, per American Journal of Transplantation\n(https://investors.imdxinc.com/news-releases/2026/06-11-2026-211734810)\n* Second study affirms superiority of iMDx GraftAssure assay’s proprietary\ndd-cfDNA Combination Model score, per Transplant International\n(https://investors.imdxinc.com/news-releases/2026/03-13-2026-120126981)\nUnder Dr. Schuetz’s leadership, iMDx’s de novo FDA submission for\nmarketing authorization of its GraftAssureDx kit earlier this year represents\na major milestone toward iMDx’s strategic goal to become the leading\nprovider of dd-cfDNA testing technology, and decentralizing access to\nmolecular diagnostic transplant rejection testing.\n\nAbout iMDx’s GraftAssure technology\n\niMDx is at a pivotal stage in commercializing its GraftAssure technology,\nwhich iMDx expects to be an industry-transforming transplanted organ rejection\nmonitoring test. The company aims to deliver proven, more affordable, faster\ntests that can be run in-house at local transplant center laboratories. iMDx\nhas designed a molecular test that it can sell as a test kit to help enable\ntransplant center laboratories to run tests locally and deliver critical test\nresults far more quickly than the current send-out tests. The company is now\nseeking FDA marketing authorization to sell these kits to transplant centers\nin the U.S.\n* Over time, iMDx sees three potential paradigm shifts in transplanted organ\nhealth monitoring:  * Bringing testing closer to the patient: The first is a\nshift in where donor-derived cell-free DNA (dd-cfDNA) testing is performed –\nmigrating out of centralized reference laboratories and into hospital-based\nlaboratories capable of delivering results locally. The company seeks to\ndemonstrate that in-house testing is better for patients and physicians. (As a\nreminder, dd-cfDNA is an established biomarker for assessing the health of a\ntransplanted organ through a simple blood draw.)\n* Expanding the clinical role of dd-cfDNA: The second is the growing potential\nfor dd-cfDNA testing, powered by digital PCR technology, to support earlier\ndetection of allograft injury, longitudinal monitoring of transplant health,\nand assessment of response to emerging anti-rejection therapies.\n* Advancing from rule-out to comprehensive decision support: The third is a\ntransition from the current rule-out-biopsy testing paradigm toward a more\ncomprehensive rule-out and rule-in approach, enabled by GraftAssure’s\nability to measure both dd-cfDNA percentage and absolute, or true,\nconcentrations as copies per milliliter of plasma.\niMDx Transplant Products and Product Candidates in Development\n\niMDx’s flagship transplant testing technology quantifies a molecular\nbiomarker known as donor-derived cell-free DNA (dd-cfDNA). The Company’s\nscientists in Germany and the U.S. have played a critical role over the past\ndecade in developing the science that helped establish dd-cfDNA as a trusted\nbiomarker of transplant rejection. iMDx is commercializing this technology\nusing a market-disruptive business strategy. Under the GraftAssure™ brand,\niMDx’s transplant diagnostics include the following:\n* GraftAssureCore – The company’s laboratory-developed test (LDT),\ncurrently reimbursed by CMS and performed at iMDx’s CLIA-certified\nlaboratory in Franklin, Tennessee.\n* GraftAssureIQ – A research-use-only (RUO) kit intended and labeled for\nnon-clinical applications.\n* GraftAssureDx – The in vitro diagnostic (IVD) kit currently under FDA\nreview for use in clinical decision-making.\nAbout Insight Molecular Diagnostics, Inc.\n\nInsight Molecular Diagnostics is a pioneering diagnostics technology company\nwhose mission is to democratize access to novel molecular diagnostic testing\nto improve patient outcomes. Investors may visit\nhttps://investors.imdxinc.com/ for more information.\n\nGraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, GraftAssure™,\nDetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular\nDiagnostics Inc.\n\nForward-Looking Statements \nAny statements that are not historical fact (including, but not limited to,\nstatements that contain words such as “will,” “believes,” “plans,”\n“anticipates,” “expects,” “estimates,” “may,” and similar\nexpressions) are forward-looking statements. These statements include those\npertaining to, among other things, expected FDA marketing authorization to\nsell GraftAssureDx, anticipated paradigm shifts in transplanted organ health\nmonitoring, transplant and other product candidates in development, and\nother statements about the future expectations, beliefs, goals, plans, or\nprospects expressed by management.   \n\nForward-looking statements involve risks and uncertainties, including, without\nlimitation, risks inherent in the development and/or commercialization of\ndiagnostic tests or products, uncertainty in the results of clinical trials or\nregulatory approvals, the capacity of Insight Molecular Diagnostics’\nthird-party supplied blood sample analytic system to provide consistent and\nprecise analytic results on a commercial scale, potential interruptions to\nsupply chains, the need and ability to obtain future capital, maintenance of\nintellectual property rights in all applicable jurisdictions, obligations to\nthird parties with respect to licensed or acquired technology and products,\nthe need to obtain third party reimbursement for patients’ use of any\ndiagnostic tests Insight Molecular Diagnostics or its subsidiaries\ncommercialize in applicable jurisdictions, and risks inherent in strategic\ntransactions such as the potential failure to realize anticipated benefits,\nlegal, regulatory or political changes in the applicable jurisdictions,\naccounting and quality controls, potential greater than estimated allocations\nof resources to develop and commercialize technologies, or potential failure\nto maintain any laboratory accreditation or certification. Actual results may\ndiffer materially from the results anticipated in these forward-looking\nstatements and accordingly such statements should be evaluated together with\nthe many uncertainties that affect the business of Insight Molecular\nDiagnostics, particularly those mentioned in the “Risk Factors” and other\ncautionary statements found in Insight Molecular Diagnostics’ Securities and\nExchange Commission (SEC) filings, which are available from the SEC’s\nwebsite. You are cautioned not to place undue reliance on forward-looking\nstatements, which speak only as of the date on which they were made. Insight\nMolecular Diagnostics undertakes no obligation to update such statements\nto reflect events that occur or circumstances that exist after the date on\nwhich they were made, except as required by law.   \n\nFDA \nCAUTION: This press release concerns certain products that are under clinical\ninvestigation, and which have not yet been cleared or authorized for marketing\nby the U.S. Food and Drug Administration. These products are currently limited\nby federal law to investigational use, and no representation is made as to the\nsafety or effectiveness of these products for the purposes for which they are\nbeing investigated. \n\nInvestor Contact: \nDouglas Farrell\nLifeSci Advisors LLC \nimdx@lifesciadvisors.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/418fe8d1-a6a4-4025-84ba-56f14ee83865)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-29T12:00:01.64545822Z","server_sent_at_ms":1782734401645},"received_at":"2026-06-29T12:00:01.758Z","source_url":"https://www.globenewswire.com/news-release/2026/06/29/3318899/0/en/IMDx-Chief-Science-Officer-Ekkehard-Schuetz-Publishes-200th-Research-Paper.html"},"analysis":{"id":"64643","press_release_id":"75297","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Insight Molecular Diagnostics Chief Science Officer Dr. Ekkehard Schuetz has published his 200th scientific article, achieving an H-index of 58 which places him in the top 2.5% of researchers globally. Dr. Schuetz is the co-inventor of the dd-cfDNA technology underlying the company's GraftAssure family of assays.\n\nHis recent publications in journals like Clinical Chemistry and American Journal of Transplantation validate the analytical sensitivity of the GraftAssure technology over NGS-based approaches. The company recently submitted a de novo FDA application for its GraftAssureDx kit to market in the U.S.\n\nCEO Josh Riggs highlighted that Dr. Schuetz's continued leadership validates the company's scientific foundation as it seeks to decentralize transplant rejection testing.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"CSO milestone reinforces scientific credibility of flagship technology."},"keyFigures":{"customDimensions":{"h_index":58,"citation_count":"more than 11,000","research_ranking":"top 2% of laboratory diagnostics researchers, top 2.5% of 2.6 million researchers worldwide","publication_count":200}},"quotedText":"His presence as Chief Science Officer is meaningfully validating for the company — the scientist who built our core technology is still running it, and we benefit from this scientific continuity.","namedEntities":{"people":[{"name":"Ekkehard Schuetz","role":"Chief Science Officer"},{"name":"Julia Beck","role":"Co-inventor"},{"name":"Josh Riggs","role":"CEO"},{"name":"Douglas Farrell","role":"Investor Contact"}],"products":["dd-cfDNA testing technology","GraftAssureCore","GraftAssureIQ","GraftAssureDx","GraftAssure","DetermaIO","DetermaCNI"],"companies":[{"name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX"},{"name":"Oncocyte Corporation","relationship":"formerly known as"},{"name":"Chronix Biomedical, Inc.","relationship":"acquired"},{"name":"University Hospital Heidelberg","relationship":"partner"},{"name":"Charité – Universitätsmedizin Berlin","relationship":"partner"},{"name":"LifeSci Advisors LLC","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Publicity milestone highlighting the CSO's publication record and scientific stature, which validates the company's proprietary technology but does not constitute a material financial or regulatory event."},"tickerRelevance":{"others":[],"primary":"IMDX"},"globalImportance":12,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/mid-cap","eventGravity":"executive_milestone","sectorWeight":"health_care"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Insight Molecular Diagnostics Chief Science Officer Dr. Ekkehard Schuetz has published his 200th scientific article, achieving an H-index of 58 which places him in the top 2.5% of researchers globally. Dr. Schuetz is the co-inventor of the dd-cfDNA technology underlying the company's GraftAssure family of assays.\n\nHis recent publications in journals like Clinical Chemistry and American Journal of Transplantation validate the analytical sensitivity of the GraftAssure technology over NGS-based approaches. The company recently submitted a de novo FDA application for its GraftAssureDx kit to market in the U.S.\n\nCEO Josh Riggs highlighted that Dr. Schuetz's continued leadership validates the company's scientific foundation as it seeks to decentralize transplant rejection testing.","key_figures":{"customDimensions":{"h_index":58,"citation_count":"more than 11,000","research_ranking":"top 2% of laboratory diagnostics researchers, top 2.5% of 2.6 million researchers worldwide","publication_count":200}},"named_entities":{"people":[{"name":"Ekkehard Schuetz","role":"Chief Science Officer"},{"name":"Julia Beck","role":"Co-inventor"},{"name":"Josh Riggs","role":"CEO"},{"name":"Douglas Farrell","role":"Investor Contact"}],"products":["dd-cfDNA testing technology","GraftAssureCore","GraftAssureIQ","GraftAssureDx","GraftAssure","DetermaIO","DetermaCNI"],"companies":[{"name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX"},{"name":"Oncocyte Corporation","relationship":"formerly known as"},{"name":"Chronix Biomedical, Inc.","relationship":"acquired"},{"name":"University Hospital Heidelberg","relationship":"partner"},{"name":"Charité – Universitätsmedizin Berlin","relationship":"partner"},{"name":"LifeSci Advisors LLC","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-29T12:22:52.290Z","global_importance":12,"audience_relevance":10,"importance_components":{"tickerTier":"small/mid-cap","eventGravity":"executive_milestone","sectorWeight":"health_care"}},"durationMs":108493,"modelName":"george-droid-qwen-72b"}}